Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis)
- PMID: 8122593
- DOI: 10.1016/0002-8703(94)90654-8
Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis)
Abstract
The purpose of this study was to determine if there are any morphologic characteristics of lesions that renarrow (that is, restenotic lesions) following successful coronary balloon angioplasty that are different from their appearance pretreatment or from the appearance of nonrestenotic lesions that might provide some new insight into the restenosis phenomenon. The study population consisted of 653 patients (778 lesions) with 6 months of angiographic follow-up (94% angiographic follow-up rate) who were participating in the Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) study. Detailed quantitative angiographic measurements, including the mean diameter of the vessel segment (in millimeters) that was subjected to balloon dilation, were performed preangioplasty, postangioplasty, and at follow-up using the cardiovascular angiographic analysis system to provide some objective measurement of the actual extent of luminal changes in the months following coronary balloon angioplasty. Two different approaches for restenosis were used: (1) static criterion of > 50% diameter stenosis at follow-up and (2) dynamic criteria of > or = 0.40 or > or = 0.72 mm change in minimal lumen diameter between postangioplasty and follow-up. Both approaches identified more severe stenosis to be a typical feature for restenotic lesions before angioplasty compared with nonrestenotic lesions. No differences were observed in lesion length, balloon-inflated vessel segment, or roughness index before angioplasty between the groups. Conflicting data were found for the amount of atherosclerotic plaque, symmetry index, and curvature index. The restenotic lesion at follow-up compared with its initial appearance gave conflicting results depending on which approach was used. The dynamic criteria illustrate that the reference diameter and the mean diameter of the entire segment dilated are reduced during follow-up. Two messages emerge from the study: (1) the restenosis process clearly involves the apparent normal vessel wall adjacent to the actual lesion, probably in response to the unavoidable injury caused by balloon dilatation and (2) the use of percentage diameter stenosis measurements depending on the assumptions of normality for a reference segment will therefore underestimate the true extent of the restenosis process and should be replaced in clinical angiographic studies by absolute luminal measurements.
Similar articles
-
Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.J Cardiovasc Pharmacol. 1993;22 Suppl 4:S45-57. J Cardiovasc Pharmacol. 1993. PMID: 7523772 Clinical Trial.
-
Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).J Am Coll Cardiol. 1992 Oct;20(4):767-80. doi: 10.1016/0735-1097(92)90171-i. J Am Coll Cardiol. 1992. PMID: 1388181 Clinical Trial.
-
Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.J Am Coll Cardiol. 1995 Feb;25(2):362-9. doi: 10.1016/0735-1097(94)00368-z. J Am Coll Cardiol. 1995. PMID: 7829789 Clinical Trial.
-
Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials.Am Heart J. 1993 May;125(5 Pt 1):1394-408. doi: 10.1016/0002-8703(93)91013-5. Am Heart J. 1993. PMID: 8480594 Review.
-
Restenosis following coronary angioplasty: clinical presentations and therapeutic options.Clin Cardiol. 1995 Dec;18(12):693-703. doi: 10.1002/clc.4960181203. Clin Cardiol. 1995. PMID: 8608668 Review.
Cited by
-
Safety and Efficacy of an Innovative Everolimus-Coated Balloon in a Swine Coronary Artery Model.Life (Basel). 2023 Oct 13;13(10):2053. doi: 10.3390/life13102053. Life (Basel). 2023. PMID: 37895434 Free PMC article.
-
Impact of post-dilatation with a focal expanding balloon for optimization of intracoronary stenting.Heart Vessels. 2007 May;22(3):152-7. doi: 10.1007/s00380-006-0952-y. Epub 2007 May 21. Heart Vessels. 2007. PMID: 17533518 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources